CN Patent

CN1683526A — 一种组蛋白甲基转移酶及其制备方法

Assigned to RUI JIN HOSPITAL AFFILIATED TO SHANGHAI SECOND MEDICAL UNIVERSITY · Expires 2005-10-19 · 21y expired

What this patent protects

本发明提供了一种新的组蛋白甲基转移酶－HSPC069SET蛋白，编码HSPC069SET蛋白的多核苷酸和经重组技术产生这种HSPC069SET蛋白的方法。本发明还公开了编码这种HSPC069SET蛋白的多核苷酸的用途。HSPC069SET蛋白具有组蛋白甲基转移功能。

USPTO Abstract

本发明提供了一种新的组蛋白甲基转移酶－HSPC069SET蛋白，编码HSPC069SET蛋白的多核苷酸和经重组技术产生这种HSPC069SET蛋白的方法。本发明还公开了编码这种HSPC069SET蛋白的多核苷酸的用途。HSPC069SET蛋白具有组蛋白甲基转移功能。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN1683526A
Jurisdiction: CN
Classification: —
Expires: 2005-10-19
Drug substance claim: No
Drug product claim: No
Assignee: RUI JIN HOSPITAL AFFILIATED TO SHANGHAI SECOND MEDICAL UNIVERSITY
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.